06.04.26 -- Distributed Manufacturing For CGT: Rent, Lease, Or Buy In An Era Of Overcapacity?

Modern medicine includes far more than familiar over‑the‑counter products. Explore how drug composition, formulation, and administration work together to shape today’s therapies.

Gene therapy requires early, rigorous safety planning and command of pediatric and biosafety rules. Early committee engagement reduces delays and strengthens high‑stakes trials.

Discover the advantages of paperless manufacturing, the importance of incorporating a digital strategy early in the process, and how digital solutions for mRNA manufacturing can help enhance production.

Learn how closed-system automation, combined with expert technical guidance and protocol optimization, turned a persistent manufacturing bottleneck into a reliable, scalable process.

Review the technical and regulatory factors in the emerging popularity of cell-free DNA.  The switch from traditional plasmid DNA to a cell-free approach requires a structured strategy for a smooth transition.

A streamlined RNA‑seq workflow enables high‑throughput gene expression profiling directly from cell lysates, reducing cost and complexity. See how this approach accelerates lead selection.

Compare how stirred-tank bioreactors overcome the scalability limitations of static culture for MSC-EV production, while Raman spectroscopy provides unprecedented real-time quality monitoring during production.

Key challenges in emerging cell therapies include finding new antigens, reducing variability, and standardizing processes. Listen as these experts also explain response differences in solid versus liquid tumors.

Reliable IFN‑γ measurement is critical for understanding T cell function. See how analytical rigor, from accuracy to matrix effects, supports consistent cytokine quantification across development.

Consider how a unique partnership model helps cell and gene therapy developers accelerate progress, reduce risk, and bring transformative therapies to market faster.